CP Pharmaceutical (Qingdao) Co., Ltd. is a new high-tech pharmaceutical enterprise which was invested in and established by CP Pharmaceutical Group. Qingdao Haier Pharmaceutical Co., Ltd., the predecessor of the company, was established in 1994. In September 2008, CP Pharmaceutical Group held 51% of the shares when establishing Qingdao Chia Tai Haier Pharmaceutical Co., Ltd., and in July 2017, CP Pharmaceutical Group held 100% of the shares. In order to achieve sustainable corporate development, the company moved to the Sino-German Ecological Park in the Qingdao West Coast New Area in July 2018.

CP Pharmaceutical (Qingdao) Co., Ltd. is the only national pilot-scale marine drug base in China, the only chiral drug research and development engineering center in Shandong Province, the Shandong Province Enterprise Technology Center, the Shandong Provincial Engineering Technology Research Center of Bone Metabolic Disease Prevention and Control Drugs, a Shandong academician work station, a key high-tech enterprise in Qingdao, an innovative marine drug engineering research center in Qingdao City, and a chemical drugs pharmaceutical engineering technology research center in Qingdao. It is a leading enterprise in the national biological industry base.

The company's products comprise four categories: marine drugs, traditional Chinese medicine, chemical drugs and health food, involving a number of fields, such as cardiovascular and cerebrovascular diseases, digestive system, osteoporosis, diabetes, nutrition healthcare, and other such fields. Among the fourteen recognized marine drugs in the world, the company owns the fifth in the world and the first in China, namely Alginic Sodium Diester and its related series of products. Gaisanchun (calcitriol soft capsules), a new state-level drug independently developed and marketed by the company, has filled a gap in China's domestic market, and won first prize in the Shandong Light Industry Science and Technology Progress Awards. At present, the domestic market share of this product has ranked first among similar varieties for seven consecutive years. In 2019, the company achieved an operating income of 1.35 billion Chinese Yuan and paid a tax of 220 million Chinese Yuan.

The annual R&D investment of the company is more than 8% of the sales income, and the annual amount is no less than 20 million Chinese Yuan. In order to build an international leading marine drug R&D platform, the company invested 100 million Chinese Yuan in establishing Marine Pharmacy (Qingdao) Innovation Base Co., Ltd. on June 21, 2018. The company has signed strategic cooperation agreements with the Marine Biomedical Research Institute of Qingdao and the Ocean University of China, and invited the academician Guan Huashi to be the company's chief scientist. The aim of this is to establish a “strategic partnership” relationship, so as to accelerate the transformation of achievements in the industry, education, research and application of marine pharmacy, and to promote the development of the marine economy.

In the future, CP Pharmaceutical (Qingdao) Co., Ltd. will adhere to the development ideas of high technology, advanced starting points, new high-speed thinking, uphold its corporate culture and concepts, persist along the road of high-tech industrialization, and continue strengthening the construction of its core competitiveness. Through school-enterprise cooperation, first-class scientific research academicians will be attracted from both home and abroad, and its scientific and efficient R&D system will be perfected, so as to accumulate great strength for further leaps and breakthroughs of industrial 4.0 intelligent manufacturing and corporate development. It shall attempt to be specialized, mighty and gargantuan in marine medicine and osteoporosis therapy. It shall continue making unremitting efforts to provide higher quality and newly-developed medical products for society, and improve the health of great masses of people.